Disease Clearance in Ulcerative Colitis: A Narrative Review

Area of Science:

• Gastroenterology
• Inflammatory Bowel Disease Research
• Clinical Trial Analysis

Background:

• Ulcerative colitis (UC) is a chronic condition with serious risks like colectomy and colorectal cancer.
• Current UC treatment guidelines (STRIDE II) focus on clinical and endoscopic remission.
• Histological remission is gaining importance, leading to the concept of disease clearance.

Purpose of the Study:

• To explore the concept of disease clearance in ulcerative colitis (UC).
• To define disease clearance as a composite outcome (clinical, endoscopic, histological remission).
• To review real-world evidence on achieving disease clearance with treatments like vedolizumab.

Main Methods:

• Narrative review of existing literature and clinical trials.
• Focus on trials evaluating vedolizumab and other biologics for UC.
• Analysis of definitions and feasibility of achieving disease clearance.

Main Results:

• Disease clearance represents comprehensive UC control, integrating multiple remission criteria.
• Achieving disease clearance may improve long-term disease course and quality of life.
• Real-world data suggest disease clearance is achievable with various treatments, including vedolizumab.

Conclusions:

• Disease clearance is a valuable, albeit challenging, target for UC management.
• It offers a more complete assessment of disease status than single remission criteria.
• Further research and standardized definitions are needed to optimize its clinical application.